Prelude Therapeutics gets FDA clearance for KAT6A degrader IND
The company said it can now move PRT13722 into a Phase 1 trial in HR+/HER2- breast cancer, with enrollment targeted for the fourth quarter of 2026.
SEC filing
Latest
2 stories
Thursday, September 10
Tuesday, August 11
Prelude reports Q2 2026 results, plans Phase 1 start for KAT6A degrader PRT13722
Prelude says it expects to initiate a Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter, pending IND clearance, while enrollment continues for PRT12396 in PV and MF.
SEC filing